Kbp Biosciences

This study tested an experimental drug called KBP-5074 in 162 people with moderate-to-severe chronic kidney disease whose high blood pressure was not well controlled. The goal was to see if the drug could safely lower blood pressure and reduce kidney damage. Participants were ran…

This study looked at how healthy men absorb, break down, and eliminate a single dose of the drug KBP-5074. Seven men took a radioactive-labeled version of the drug so researchers could track it in blood, urine, and stool. The goal was to understand the drug's metabolism and how i…

This early-phase study tested the safety and how the body processes a new drug called KBP-5074 in 46 healthy adults. Researchers gave single doses and monitored side effects, vital signs, and drug levels in the blood. The goal was to gather information needed for future studies i…

This early-stage study tested a single dose of the experimental drug KBP-5074 in 11 people with severe chronic kidney disease, including some on dialysis. The main goal was to check safety and how the drug moves through the body. No treatment benefits were measured; the study was…

This study looked at how the drug KBP-5074 behaves in people with moderate liver impairment compared to healthy adults. Twelve participants received a single dose to measure drug levels and check for side effects. The goal is to understand if liver problems change how the drug is…

This early-stage study tested the safety and how the body processes KBP-5074 in 26 healthy adults and people with mild to moderate kidney impairment. Researchers measured side effects and drug levels in the blood to help design future larger studies. No treatment was given; the g…

This study tested a new tablet form of the experimental drug KBP 5074 against the current capsule form in 20 healthy adults aged 18 to 45. Researchers measured how the drug moves through the body and checked for side effects. The results will help decide which dose to use in futu…

This study looked at how two common drugs (itraconazole and rifampin) change the levels of KBP-5074 in the blood of 24 healthy adults. It was a phase 1 trial with no treatment for any disease. The goal was to gather safety and dosing information for future research.